LNAI

Lunai BioworksA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

10%

Probability

Target price

$0.45

Analysis reference price unavailable

Analysis 2026-10-25 · RankAlpha Sentiment Codex

Base case

35%

Probability

Target price

$0.18

Analysis reference price unavailable

Analysis 2026-10-25 · RankAlpha Sentiment Codex

Most likely

B-

Bear case

55%

Probability

Target price

$0.03

Analysis reference price unavailable

Analysis 2026-10-25 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-25

AI commentary

The October 23 filing materially worsens the prior monitoring thesis: Nasdaq's delisting determination and the company's decision not to seek a hearing replace an uncertain exchange response with a dated suspension path. The $0.2946 October 23 anchor is the only supplied current price; a post-filing price reaction cannot be measured from the packet. No current analyst-revision, social, options, short-interest or employee data were supplied; zero sentiment fields mean unavailable, not neutral.

RankAlpha Sentiment Codex - 2026-10-25

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report; small-cap biotech memo lacks a distinct long-horizon program, partnership, or financing catalyst for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-10-30eventExpected Nasdaq trading suspensionHigh impact

Nasdaq determined to delist LNAI. Unless the company requests a hearing by October 28, trading is scheduled to be suspended at the October 30 open; the company says it does not intend to request one. This supersedes the prior memo's unresolved Nasdaq-response catalyst. [#8-K-2026-10-23] SEC filing

2026-11-12eventPlanned Form 25 filing and delistingHigh impact

Lunai intends to file Form 25 around November 2 and expects delisting around November 12. It does not intend to arrange OTC quotation and cannot assure any trading market will remain after suspension. The dates and market outcome are not guaranteed. [#8-K-2026-10-23] SEC filing

2026-11-30catalystFinancing or operating retrenchmentHigh impact

The prior baseline cites the FY2026 10-K as saying the company had less than one month of available cash resources on October 13 and needed financing for near-term operations. The October 23 filing also cites the company's financial condition and a $9.0 million stockholders' deficit. No financing transaction is confirmed; dilution or failure to fund operations remains a material risk. [#10-K-2026-10-13] [#8-K-2026-10-23] SEC filing

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-25 • Updated nightlySource: Internal modelMethodology